Arbutus Biopharma (ABUS) to Release Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $2.54 million for the quarter.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The business had revenue of $1.57 million for the quarter, compared to analysts’ expectations of $2.20 million. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arbutus Biopharma Stock Performance

Shares of NASDAQ ABUS opened at $3.34 on Tuesday. Arbutus Biopharma has a fifty-two week low of $2.63 and a fifty-two week high of $4.73. The stock has a market cap of $639.54 million, a price-to-earnings ratio of -7.77 and a beta of 1.45. The firm’s 50-day simple moving average is $3.28 and its 200 day simple moving average is $3.44.

Analyst Ratings Changes

Several research firms have commented on ABUS. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 29th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Finally, Chardan Capital reissued a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.